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Background: Better knowledge of distribution of respiratory viruses (RVs) in adolescents and adults with
community-acquired pneumonia (CAP) is needed.
Methods: To investigate the RVs etiology among adolescents and adults with CAP, according to age and pneumonia
severity index (PSI), a multi-center, prospective study was conducted from November 2010 to April 2012. Fifteen RVs
were tested by polymerase chain reaction (PCR). Bacteria were detected by urinary antigen, conventional culture and
PCR.
Results: Mean (SD) age and median (IQR) PSI score of 954 patients enrolled was 45.2 (19.5) years (range 14–94) and 42
(36). RVs were found in 262 patients (27.5%): influenza virus A (IFV A, 9.9%) comprised of pandemic H1N1 (6.7%) and
seasonal H3N2 (3.5%), human rhinovirus (4.3%), adenovirus (4.2%), human metapneumovirus (1.8%), parainfluenza virus
1, 3 and 2 (1.7%, 1.5% and 1.2%). Influenza virus B, enterovirus, respiratory syncytial virus, human coronavirus and
parainfluenza virus 4 were rarely detected (<1%). Frequency of IFV A was highest among patients aged between 45–64
years (p < 0.001), while adenovirus among patients aged 14–17 years (p < 0.001), no differences was found in other
RVs. The proportion of pandemic H1N1 increased with severity of pneumonia evaluated by PSI (P < 0.05).
Conclusions: The proportion of RVs in CAP is higher than previously reported. IFV A pneumonia are usually found in
patients older than 45 years, while, adenovirus pneumonia are common in adolescents and young adults. Pandemic
H1N1 virus is still recognized by PSI as a high-severity pathogen. The findings contribute baseline data on viral CAP
study in China.
Keywords: Community-acquired pneumonia, Respiratory viral infection, Pneumonia severity index, Adolescent, Adult,
Influenza virus A, Adenovirus, Human rhinovirusBackground
Community-acquired pneumonia (CAP) remains a com-
mon disease associated with significant morbidity and
mortality. Mortality varied from <1% to 48% and is as-
sociated with advanced age, co-morbid conditions, and
CAP severity [1]. Clear etiology is essential for the* Correspondence: cabin_ben@163.com
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unless otherwise stated.management of CAP patients [2]. Although CAP guide-
lines acknowledge respiratory viruses (RVs) as a “cause”
of adults pneumonia [3], few recommendations are
made regarding management, largely due to the short
of data regarding prevalence and clinical severity, as
most relevant data concern infants and children [4,5].
In addition, the emergence of severe acute respiratory
syndrome (SARS), avian influenza A (H5N1) virus, and
the pandemic influenza A 2009 (pH1N1) virus has em-
phasized the important role of RVs as causes of CAP
[6]. Thus, much better knowledge of the potential roles is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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pneumonia is needed.
In general, compared to conventional viral diagnostic
methods (culture, antigen detection, and serological as-
says), PCR-based methods are 2–5 times more sensitive
to detect RVs [6]. Moreover, use of PCR has augmented
detection of viruses that are difficult to identify with
conventional methods, including human rhinovirus
(HRV), human coronavirus (hCoV), human metapneu-
movirus (hMPV), and human bocavirus [7,8]. Recently,
development of several multiplex assays has enabled
simultaneous detection of up to 15 different viruses,
and use of these tests is becoming standard for identifi-
cation of respiratory viruses [9-11].
In an attempt to better characterize the viral etiology
of CAP in adolescents and adults, a multi-center, pro-
spective surveillance was conducted in 12 general hospi-
tals of Beijing, from November 2010 to April 2012, using
a multiplex RT-PCR assay covering all common RVs as-
sociated with CAP [12]. We also sought to evaluate age
and severity of disease related to different pathogens.Methods
Study setting and design
A prospective study was conducted in 12 general hospi-
tals in Beijing, covering 80% of 30 million citizens, as
described in former report [13]. Between November
2010 and April 2012, patients (aged 14 years or above)
who came to the hospitals during daytime and met the
inclusion criteria of CAP [3] were enrolled. Patients
with HIV infection; neutropenia or chemotherapy; preg-
nant; known or suspected active tuberculosis, no informed
consents or specimens were excluded. The study was ap-
proved by institutional review board in Beijing Chao-Yang
Hospital (project approval number: 10-KE-49). Written
informed consents were provided by all adults and the
parents of patients aged less than 18 years.Patient characteristics and CAP scoring system
The following data were recorded on enrollment: age,
gender, smoking status, comorbid illnesses and anti-
microbial treatment prior to enrollment, duration of
symptoms prior to visit, clinical symptoms, physical
examination, chest X-ray or computed tomography
(CT) scan pattern, blood analysis and antimicrobial and
antiviral treatment. All surviving patients were followed-
up by telephone after discharge for four weeks, symp-
toms and signs were recorded daily. Pneumonia sever-
ity index (PSI) score classes were assigned according to
the authors’ original designations [14]. PSI classes were
specified as follows: low risk = I-II, moderate risk = III,
high risk = IV-V.Microbiological evaluation
Microbiological examination was performed in throat
swab, sputum, urine and blood, at the central laboratory
(Clinical Microbiological Laboratory of Beijing Chao-
Yang Hospital). The etiology was considered definite if
one of the following criteria was met: (1) positive urinary
antigen for Legionella pneumophila (LP, Binax Now L
pneumophila urinary antigen test; Trinity Biotech, Bray,
Ireland); (2) positive urinary antigen for Streptococcus
pneumoniae (Binax Now S pneumoniae urinary antigen
test; Emergo Europe, The Netherlands); (2) positive bac-
terial culture from blood. The etiology was considered
probable if one of the following criteria was met: (1) de-
tection of RVs in throat swabs by RT-PCR using a See-
plex RV Detection Kit (Seegene Biotechnology Inc.,
Seoul, Korea) according to manufacturer’s instructions,
including respiratory syncytial virus (RSV) types A and
B, influenza virus (IFV) types A and B, parainfluenza
virus (PIV) types 1, 2, 3 and 4, HRV, enterovirus (EV),
hCoV types 229E, NL63, OC43 and HKU1, hMPV, and
adenovirus (AdV), bocavirus; (2) purulent sputum (de-
fined as an adequate quality sputum sample with > 25
leukocytes and < 10 epithelial cells per × 100 magnifica-
tion field) with compatible findings of Gram staining; (3)
detection of Mycoplasma pneumoniae (MP) in throat
swabs by PCR as previously reported [15].
Statistical analysis
Categorical variables were described with counts and
percentages. Data for continuous variables were pre-
sented as mean (SD) or median (IQR) where appropri-
ate. The proportions of individuals in each age and PSI
groups diagnosed with each pathogen of interest were
compared using χ2 tests (SPSS for Windows 13.0).
Results
Patient characteristics
As seen in Figure 1, a total of 1013 adult CAP patients
met the criteria were screened. Because of failing in
sampling or follow-up, or confirmed with tuberculosis
or non-pneumonia diseases (including lung cancer and
etc.), 59 patients were excluded. Finally, etiological and
clinical analysis was conducted on 954 patients (94.2%),
and 56.6% were males. The mean (SD) age was 45.2
(19.5) years (range 14–94), 184 (19.4%) were aged ≥ 65
years.
The main demographic and clinical characteristics of
the study population are summarized in Table 1. One
hundred and eighty-four (19.3%) patients had comorbid-
ities record, such as coronary heart diseases (8.1%),
diabetes (7.6%), chronic obstructive pulmonary disease
(2.3%) and etc. 254 (26.6%) patients had smoking history.
Within one year, 40 (4.2%) and ten (1%) patients had
received influenza and streptococcus pneumonia vaccine.
Figure 1 Participants screening and enrollment.
Table 1 Epidemiological and clinical characteristics of
study population
Characteristics n (%)
Total number of patients 954
Demographic data
Age (years), mean ± SD 45.2 ± 19.5
Gender male 540 (56.6)
Comorbidities 184 (19.3)
Coronary heart diseases 77 (8.1)
Diabetes 73 (7.6)
Chronic obstructive pulmonary disease 22 (2.3)
Smoking (present or past) 254 (26.6)
Influenza vaccine received within 1 year 40 (4.2)






Antibiotics received before enrollment 625 (65.5)
Symptoms
Fever 878 (92)
Tmax (°C), mean ± SD 39.0 ± 0.7
Cough 875 (91.7)
Sputum 672 (70.4)
Shortness of breath 137 (14.4)
Chest pain 116 (12.2)
Laboratory findings
Procalcitonin (n = 130), median (IQR) 0.17 (0.42)
C reactive protein (n = 671), median (IQR) 42.5 (86.8)
WBC count (×109/L), median (IQR) 7.6 (4.7)
WBC > 10 (×109/L) 257 (26.9)
WBC < 4 (×109/L) 61 (6.4)
Antimicrobial treatment after enrollment
Antibiotics 918 (96.2)
Antivirals 26 (2.7)
Length of hospital stay (days) 9 (6–14)
PSI, median (IQR) 42 (36)
Death 4 (0.4)
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hospitalized, including six (0.6%) in ICUs. Six hundred
and twenty-five patients (65.5%) had received antimicro-
bial treatment prior to enrollment. Common symptoms
of the patients were fever (92%), cough (91.7%) and spu-
tum production (70.4%). After admission, 918 patients
(96.2%) and 26 patients (2.7%) received antimicrobial
and antiviral treatment. Median (IQR) score of PSI was
42 (36). Four patients (0.4%) died within four weeks.
Distribution of pathogens
Etiological diagnoses were established in 393 patients
(41.2%), as shown in Table 2. The positive rate of RVs
was 27.5%. IFVA was dominant (9.9%, 94/954). There
were 60 cases of pH1N1, 30 cases of seasonal H3N2
(sH3N2) and four cases of both subtypes. Seven patients
infected with pH1N1 had received influenza vaccine
within one year. The detection rate of HRV was 4.3%,
and followed by AdV, 4.2%; hMPV, 1.8%; PIV1, 1.7%;
PIV3, 1.5%; PIV2, 1.2%; and IFVB, EV, RSVs, hCoV and
PIV4 were rarely detected (<1%). No bocavirus was
detected.
The positive rate of bacteria was 23%. Atypical bac-
terial pathogens, including Mycoplasma pneumoniae
and Legionella pneumophila, were detected in 168 (17.6%)
and four (0.4%) patients. Strectococcus pneumoniae was
detected by urine antigen test in fifteen patients. In 533
CAP patients available with bacterial culture, typical
bacterial pathogens were detected in 32 patients, mainly
consisted of Klebsiella pneumoniae, Pseubomonas aerugi-
nosa, Streptococcus pneumoniae and Haemophilus influen-
zae (data not shown).There were 257 patients with hyperleucocytosis, as
shown in Table 1. Among these patients, 42 bacterial
pathogens (including Mycoplasma pneumomniae, Strepto-
coccus pneumoniae, Haemophilus influenzae and etc.) and
62 viral pathogens (including human rhinovirus, influenza
virus A, adenovirus and etc.) were detected. Mean (SD)
score of PSI of hyperleucocytosis group was significantly
Table 2 Etiology of study population with CAP
Pathogen identified n (%)
At least one pathogen 393 (41.2)
Respiratory viruses (RVs) 262 (27.5)
Influenza virus A 94 (9.9)
Pandemic H1N1 (pH1N1) 60 (6.3)
Seasonal H3N2 (sH3N2) 30 (3.1)
pH1N1 and sH3N2 4 (0.4)
Human rhinovirus 41 (4.3)
Adenovirus 40 (4.2)
Human metapneumovirus 17 (1.8)
Parainfluenza virus type 1 16 (1.7)
Parainfluenza virus type 3 14 (1.5)
Parainfluenza virus type 2 11 (1.2)
Influenza virus B 6 (0.6)
Enterovirus 5 (0.5)
Respiratory syncytial virus type A 5 (0.5)
Respiratory syncytial virus type B 4 (0.4)
Human coronavirus types OC43/HKU1 4 (0.4)
Human coronavirus types 229E/NL63 4 (0.4)
Parainfluenza virus type 4 1 (0.1)
Bocavirus 0 (0)
Bacteria 219 (23.0)
Mycoplasma pneumoniae 168 (17.6)
Legionella pneumophila 4 (0.4)
Typical bacteria 47
Data are expressed as n (%).
Table 3 Distribution of co-infections
Associations n (%)
Dual infections 65 (6.8)
RV + Bacterium 48
IFV A + Bacterium 19
HRV + Bacterium 9
PIVs + Bacterium 8
AdV + MP 4
hCoVs + MP 2
IFV B + MP 2
RSVs + MP 2
hMPV + Bacterium 2
RV + RV 11
IFV A + hCoVs 2
IFV A + PIVs 2
HRV + PIVs 2
hMPV + PIVs 2
AdV + RSV A 1
AdV + PIVs 1
AdV + hCoVs 1
Bacterium + Bacterium 6
Triple infections 8 (0.84)
IFV A (sH3N2) + PIV1 + PIV2 1
IFV A (sH3N2) + PIV2 + PIV3 1
IFV A (pH1N1) + two Bacteria 1
HRV + PIV1 + PIV3 1
HRV + two bacteria 1
PIV1 + EV + bacterium 1
PIV1 + PIV3 + bacterium 1
IFV B + AdV + PIV3 1
Quadruple infection 1 (0.1)
PIV1 + PIV3 + two bacteria 1
Quintuple infections 1 (0.1)
HRV + PIV1 + PIV2 + PIV3 + RSV B 1
Total 75/954 (7.9)
Note: influenza virus (IFV) types A and B, human rhinovirus (HRV), adenovirus
(AdV), human metapneumovirus (hMPV), parainfluenza virus (PIV) types 1, 2, 3
and 4, enterovirus (EV), respiratory syncytial virus (RSV) types A and B, human
coronaviruses (hCoVs), Mycoplasma pneumoniae (MP).
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25.03 v.s. 43.98 ± 25.37, p < 0.001).
Two or more causative agents were found in 75 pa-
tients (7.9%), as shown in Table 3. The common associa-
tions among dual infections were: a RV and a bacterium
in 48 cases (64%), two RVs in 11 cases (14.7%) and two
bacteria in six cases (8%). Triple, quadruple and quintu-
ple infections were detected. IFV A, detected in 26 cases,
was the most frequently RV in co-infections. PIVs were
co-detected in 23 cases, HRVs in thirteen, AdVs in eight,
hCoVs in five, RSVs and hMPVs in four, IFVs B in three,
and EV in one.
Regarding on antiviral treatment, there were 16 pa-
tients received oseltamivir among 94 IFV A infections.
The clinical analysis of antiviral treatment revealed that
the median length of hospitalization of antiviral group
was significantly shorter than that of non-antiviral group
(5.5 days v.s. 8 days, p = 0.04).
Two of the four dead patients were positive with
pH1N1, the other two were positive with Streptococcus
pneumoniae and Klebsiella pneumoniae, and Legionella
pneumophila and human rhinovirus.Microbial etiology in age groups
The study population was divided into four groups by
age, 14 ~ 17 years (adolescents), 18 ~ 44 years (young
adults), 45 ~ 64 years (old adults) and ≥ 65 years (eld-
erly) as shown in Table 4, to look for pathogens more
commonly associated with an age group. The microbial
etiology was determined in 70%, 44.5%, 37.9% and 30.3%
for four groups respectively (p < 0.001), and co-infection
rate decreased (14%, 9%, 5.9% and 6.3% respectively).
Table 4 Etiology of CAP according to age
Etiology 14 ~ 17 yrs (n = 50) 18 ~ 44 yrs (n = 443) 45 ~ 64 yrs (n = 272) 65 ~ 94 yrs (n = 189) p value
At least one pathogen 35 (70) 197 (44.5) 103 (37.9) 58 (30.3) <0.001
Respiratory viruses (RV) 15 (30) 104 (23.5) 72 (26.5) 45 (23.8) 0.651
IFV Ad 2 (4) 32 (7.2) 38 (14) 22 (11.6) <0.001
pH1N1 2 (4) 20 (4.5) 24 (8.8) 14 (7.4) 0.743
sH3N2 0 9 (2) 14 (5.1) 7 (3.7)
pH1N1 and sH3N2 0 3 (0.7) 0 1 (0.5)
HRV 2 (4) 19 (4.3) 13 (4.8) 7 (3.7) 0.962
AdVabcd 7 (14) 23 (5.2) 5 (1.8) 5 (2.6) <0.001
HMPV 0 6 (1.4) 6 (2.2) 5 (2.6) 0.524
PIV 1 2 (4) 8 (1.8) 2 (0.7) 4 (2.1) 0.236
PIV 3 2 (4) 7 (1.6) 3 (1.1) 2 (1.1) 0.384
PIV 2 1 (2) 9 (2) 1 (0.4) 0 0.053
IFV B 1 (2) 3 (0.7) 1 (0.4) 1 (0.5) 0.495
EV 1 (2) 3 (0.7) 1 (0.4) 0 0.301
RSVA 0 4 (0.9) 1 (0.4) 0 0.628
RSV B 0 4 (0.9) 0 0 0.351
HCoV OC43/HKU1 0 2 (0.5) 2 (0.7) 0 0.739
HCoV 229E/NL63 0 3 (0.7) 1 (0.4) 0 0.853
PIV 4 0 1 (0.2) 0 0 1.000
Bacteria 26 (52) 120 (27.1) 44 (16.2) 27 (14.3)
MPabcde 25 (50) 106 (23.9) 24 (8.8) 13 (6.9) <0.001
LP 1 (2) 2 (0.5) 1 (0.4) 0 0.262
Typical bacteriacde 0 12 (2.7) 19 (7) 14 (7.4) 0.005
Two or more pathogens 7 (14) 40 (9) 16 (5.9) 12 (6.3) 0.141
Data are expressed as n (%).
a: p < 0.05, 14 ~ 17 yrs group vs 18 ~ 44 yrs group;
b: p < 0.05, 14 ~ 17 yrs group vs 45 ~ 64 yrs group;
c: p < 0.05, 14 ~ 17 yrs group vs 65 ~ 94 yrs group;
d: p < 0.05, 18 ~ 44 yrs group vs 45 ~ 64 yrs group;
e: p < 0.05, 18 ~ 44 yrs group vs 65 ~ 94 yrs group;
Note: influenza virus (IFV) types A and B, human rhinovirus (HRV), adenovirus (AdV), human metapneumovirus (hMPV), parainfluenza virus (PIV) types 1, 2, 3 and 4,
enterovirus (EV), respiratory syncytial virus (RSV) types A and B, human coronavirus (hCoV) types 229E, NL63, OC43 and HKU1, Mycoplasma pneumoniae (MP) and
Legionella pneumophila (LP).
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erly groups (p < 0.001). HRV was equally detected in all
age groups. The frequency of AdV decreased according
to the four groups (p < 0.001), and similar trend was
found in PIV 2 (p = 0.053) and MP (p < 0.001). No
hMPV was detected in adolescents, and no RSV or
hCoV was found in adolescents and elderly adults. The
frequencies of typical bacterial pathogens increased
according to age group (p = 0.005).
Microbial etiology according to severity score
To explore the association between pathogens and the
severity score, patients were also separated into three
groups according to severity score (PSI), as indicated in
Table 5. In three groups, though pathogens detection
rates were different, RVs ranked first (25.1%, 19.5% and30.4%, respectively). All RVs were detected in low risk
group. The frequency of IFV A increased along with se-
verity (from 9.4% and 8.8% to 17.9%). Significant differ-
ence (p = 0.018) was found in subtypes of IFV A among
PSI groups, especially for pH1N1 (p < 0.05). Similar
trend was found in the distribution of typical bacterial
pathogens (p = 0.001). The distributions of HRV, AdV
and hMPV in three groups were comparable. The fre-
quency of MP decreased in moderate- and high-risk
groups, whereas that of the mixed etiology decreased
first (5.3%), then increased (8.9%).
Discussion
To our knowledge, this is the largest scale investigation
of common RV infections in China in adolescents and
adults with CAP, using PCR-based method. The CAP
Table 5 Etiology of CAP according to PSI
PSI I-II (n = 785) PSI III (n = 113) PSI IV-V (n = 56) p value
At least one pathogen 333 (42.5) 35 (29) 25 (44.6) 0.219
Respiratory viruses (RV) 197 (25.1) 22 (19.5) 17 (30.4) 0.267
IFV A 74 (9.4) 10 (8.8) 10 (17.9) 0.118
pH1N1bc 42 (5.4) 8 (7.1) 10 (17.9) 0.018
sH3N2 28 (3.6) 2 (1.8) 0
pH1N1 and sH3N2 4 (0.5) 0 0
HRV 33 (4.2) 5 (4.4) 3 (5.4) 0.854
AdV 36 (4.6) 3 (2.7) 1 (1.8) 0.542
HMPV 14 (1.8) 1 (0.9) 2 (3.6) 0.391
PIV 1 15 (1.9) 1 (0.9) 0 0.668
PIV 3 13 (1.7) 0 1 (1.8) 0.445
PIV 2 10 (1.3) 1 (0.9) 0 1.000
IFV B 6 (0.8) 0 0 1.000
EV 4 (0.5) 1 (0.9) 0 0.624
RSVA 4 (0.5) 1 (0.9) 0 0.624
RSV B 4 (0.5) 0 0 1.000
HCoV OC43/HKU1 4 (0.5) 0 0 1.000
HCoV 229E/NL63 4 (0.5) 0 0 1.000
PIV 4 1 (0.1) 0 0 1.000
Bacteria 187 (23.9) 17 (15.1) 13 (23.2)
MPa 157 (20) 6 (5.3) 5 (8.9) <0.001
LP 2 (0.3) 2 (1.8) 0 0.146
Typical bacteriaab 28 (3.6) 9 (8) 8 (14.3) 0.001
Two or more pathogens 64 (8.2) 6 (5.3) 5 (8.9) 0.562
Data are expressed as n (%).
a: p < 0.05, PSI I-II vs III;
b: p < 0.05, PSI I-II vs IV-V;
c: p < 0.05, PSI III vs IV-V;
Note: influenza virus (IFV) types A and B, human rhinovirus (HRV), adenovirus (AdV), human metapneumovirus (hMPV), parainfluenza virus (PIV) types 1, 2, 3 and 4,
enterovirus (EV), respiratory syncytial virus (RSV) types A and B, human coronavirus (hCoV) types 229E, NL63, OC43 and HKU1, Mycoplasma pneumoniae (MP) and
Legionella pneumophila (LP).
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studies with specific feathers as below, (1) young, mean
(SD) age was 45.24 (19.478) years; (2) 82.3% of the
patients’ PSI classes wereI-III; (3) low numbers of ICU
admission and deaths; (4) 9 of 12 teaching hospitals
functioned as primary care facilities. Our results indi-
cated that 27.5% of CAP patients have evidence of viral
infection. It has been generally assumed that for respira-
tory infections due to viruses, the optimal specimen is
the nasopharyngeal aspirate, rather than throat swabs we
used here [16]. Actually, the detection rate was higher
than 22% reported by Ruuskanen O et al. [6] based on
2910 CAP patients from 10 studies, also higher than
5–20% reported by other studies that had not used PCR-
based assays [17].
IFV A was the first ranking viral pathogen. Among 94
cases, 68 (72.3%) had IFV A as the only identified patho-
gen, 20 (21.3%) had co-infection with bacteria, and six(6.4%) had co-infection with other RVs. Similar with
other reports [18,19], the analysis of subtypes of IFV A
revealed that pH1N1 virus was circulating along with
sH3N2 virus, as this surveillance was carried out from
the post-pandemic period of pH1N1 [20]. It has been
reported that younger age and more severe respiratory
compromise are key features of patients with pH1N1-
associated pneumonia compared with seasonal influenza
pneumonia [21]. Here, oppositely, pH1N1 infected pa-
tients were mostly distributed in patients older than 45
years, which was coincident with the findings reported
by Viasus D et al. [22]. This upward shift in age distribu-
tion is probably due to a higher seropositivity against A
(H1N1) pdm09 virus in young adult patients. On the
other side, although IFV A infected cases distributed
through all PSI groups, all cases in high risk group were
determined as pH1N1 (accounting for 16.7%, p < 0.05).
And 93.3% of sH3N2 positive patients were found in low
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patients were caused by pH1N1. These findings suggest
that the severity of pH1N1-associated CAP is still higher
[22]. Four co-infection cases of pH1N1 and H3N2 were
presented with PSI I-II, the reason was unclear. Further
analysis of corresponding viral load and antiviral treat-
ment might be needed.
In agreement with our results (HRV, 4.3%), two re-
cently reports using PCR assays suggested that HRV
was important cause in CAP, with infection rates of
4.9% [23] and 7% [24]. Among 41 infections, 27 pa-
tients (65.9%) had HRV as the only identified pathogen,
ten (24.4%) had co-infection with bacteria, and four
(9.7%) had co-infection with other RVs. These results
stand in contrast to those of previous studies, which re-
ported that HRV commonly occurred with bacterial co-
infection (approximately 41.9–57.1%) [25,26]. Moreover, it
is reported that HRV single or mixed HRV /pneumococcal
infection should be an independent cause of severe pneu-
monia [25-27]. In our study, oppositely, HRV infections
occurred in all age and severity groups.
The incidence of adenovirus was 4.2%, which was in
the upper scale of the range of < 1% - 4% as reported
[12]. Although most infected cases are self-limited,
adenovirus is recognized as one of the first viruses
clearly linked with pneumonia [12]. David Lieberman’s
team had found that 1.6% of adults CAP patients caused
by adenovirus, and no such cases had been detected in
healthy controls or non-pneumonia low respiratory tract
infection cohort [23]. Few studies reported on the co-
infection of adenovirus with other pathogens, here, we
found four with MP and four with other RVs, accounting
for 20%. Lauderdalea et al. reported that all infections of
AdV were found in 17–44 years-old patients [28]. Simi-
larly, the incidence was significantly higher in adoles-
cents and younger adults (p < 0.001).
Regarding on other important viruses, the frequencies
of PIVs, RSV, hMPV and HCoVs were lower than that of
Dr. Andrew T. Pavia’s report [12]. Since most respiratory
viruses are highly seasonal, the frequencies might be in-
fluenced by the variation in intensity of the study period,
age of the population and region.
In this surveillance, CAP patients due to MP, an im-
portant atypical bacterial pathogen, were common in
14 ~ 44 years-old patients and recognized by PSI as a
low-risk condition, which is in consistent with the previ-
ous findings [29,30]. Just as Roson et al. reported, the
patients with bacterial infections were usually associated
with increased severity and mortality [31]. The analysis
of typical bacterial pathogens indicated that the inci-
dence increased along with age and PSI classes of the
patients. And one patient died from co-infection of
Streptococcus pneumoniae and Klebsiella pneumoniae.
However, bacterial pneumonia might be underdiagnosedin this study [1,32] due to the reasons: (1) we focused on
viral pathogens, therefore patients unavailable with a
blood or sputum culture were not excluded. Only 533
patients were detected for typical bacterial pathogens,
though urinary antigen test was conducted in all pa-
tients; (2) the defined population was young and had
low or moderate severity; (3) the rate of antimicrobial
treatment before enrollment was high (65.5%).
Our study is subject to two limitations. First, as re-
ported by David Lieberman [23], RVs could be detected
in 7.1% of 450 controls without respiratory complaints.
Healthy controls were not included to clarify the clinical
significance of RVs, especially for the cases of triple and
quadruple infections. Second, clinical relevance of viral
load in the specimens could not be analyzed since the
study was carried out in qualitative assays.
Conclusions
The proportion of RV involvement in CAP is higher
than previously reported. Influenza virus A pneumonia
are usually found in patients older than 45 years, while,
adenovirus pneumonia are commonly found in adoles-
cents and young adult patients. Pandemic H1N1 virus is
still recognized by PSI as a high-severity pathogen. The
findings contribute baseline data on viral CAP study in
China.
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